Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Blacks Fare Better After This Type of Transplant
Biol Blood Marrow Transplant.; ePub 2018 Jan 25; Solomon, et al
Black patients appear to experience less disease relapse than whites following post-transplant cyclophosphamide-based haploidentical donor transplantation (PTCy-HIDT), according to an analysis involving 203 individuals. Participants were a median age of 53 years and comprised blacks (n=80) and whites (n=123) who underwent first PTCy-HIDT for hematologic malignancies at a single center. Peripheral blood stem cell was used in two-thirds of patients, and 4 in every 10 received myeloablative conditioning. Among the results:
- 3-year overall survival, disease-free survival, and relapse rates in blacks were 72%, 65%, and 25%, respectively.
- These rates in whites were 50%, 45%, and 39%, respectively.
- Non-relapse mortality, acute graft-versus-host disease (GVHD), and moderate-to-severe chronic GVHD rates were similar in both groups.
- Improved survival was seen in all black patient subgroups.
- Blacks were 53% more likely than whites to experience better overall survival.
- They were 51% more likely to experience better disease-free survival.
Solomon S, Zhang X, Holland H, Morris L, Solh M, Bashey A. Superior survival of black versus white patients following post-transplant cyclophosphamide-based haploidentical transplantation for adults with hematologic malignancy. [Published online ahead of print January 25, 2018]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2018.01.024.